<?xml version="1.0" encoding="UTF-8"?>
<p id="p0120">Moreover, a recent report by Tang et al. (2020) demonstrated that anticoagulant therapy with heparin (mainly with low molecular weight heparin) was associated with better prognosis in severe COVID-19 patients. The 28-day mortality of heparin users was lower than that of non-users among patients with sepsis-induced coagulopathy scores ≥4 (40.0% vs. 64.2%, 
 <italic>P</italic> = 0.029), or D-dimer &gt; 6-fold the upper limit of normal (32.8% vs. 52.4%, 
 <italic>P</italic> = 0.017).
 <xref rid="bib69" ref-type="bibr">
  <sup>69</sup>
 </xref>
</p>
